Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

113.06USD
27 May 2016
Change (% chg)

$0.16 (+0.14%)
Prev Close
$112.90
Open
$113.04
Day's High
$113.34
Day's Low
$112.69
Volume
1,777,802
Avg. Vol
2,742,031
52-wk High
$115.00
52-wk Low
$81.79

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.59
Market Cap(Mil.): $310,987.81
Shares Outstanding(Mil.): 2,750.64
Dividend: 0.80
Yield (%): 2.83

Financials

  JNJ.N Industry Sector
P/E (TTM): 20.61 35.22 36.14
EPS (TTM): 5.49 -- --
ROI: 14.06 13.74 13.10
ROE: 21.89 14.88 14.37

California sues Johnson & Johnson over marketing for pelvic mesh

NEW YORK California has accused Johnson & Johnson of failing to warn doctors and patients about the severity and frequency of complications associated with its pelvic mesh devices.

25 May 2016

UPDATE 2-California sues Johnson & Johnson over marketing for pelvic mesh

NEW YORK, May 24 California has accused Johnson & Johnson of failing to warn doctors and patients about the severity and frequency of complications associated with its pelvic mesh devices.

25 May 2016

J&J to stand behind talc's safety at upcoming trials: lawyer

NEW YORK Johnson & Johnson will keep arguing in court that its talc-based powders are safe, an outside lawyer who has defended the company in lawsuits said, even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.

19 May 2016

REFILE-J&J to stand behind talc's safety at upcoming trials -lawyer

NEW YORK, May 17 Johnson & Johnson will keep arguing in court that its talc-based powders are safe, an outside lawyer who has defended the company in lawsuits said, even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.

19 May 2016

J&J to stand behind talc’s safety at upcoming trials - lawyer

NEW YORK Johnson & Johnson will keep arguing in court that its talc-based powders are safe, an outside lawyer who has defended the company in lawsuits said, even after losing two multi million-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.

18 May 2016

BRIEF-Johnson & Johnson says collaborating with HP Inc's unit

* Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies

17 May 2016

Reverse Yankees storm heavily supplied European bond market

LONDON, May 11 (IFR) - The expected rush of reverse Yankee supply materialised on Wednesday with Johnson & Johnson, Kraft Heinz and General Motors offering investors enticing premiums to sell multi-tranche bond issues against a weaker market backdrop.

11 May 2016

Fitch Rates Johnson & Johnson's Euro Notes Offering 'AAA'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, May 11 (Fitch) Fitch Ratings has assigned a 'AAA' rating to Johnson & Johnson's (JNJ) euro notes offering. The Rating Outlook is Stable. JNJ intends to use the net proceeds from the issuance for share repurchases, debt reduction and general corporate purposes. A complete list of JNJ's ratings follows at the end of this press release. KEY RATING DRIVERS The company's 'AAA' rating reflects the following: --JNJ continues to ge

11 May 2016

European corporate glut goes unabated but fatigue looms

LONDON, May 10 (IFR) - The relentless pace of corporate issuance showed no signs of abating on Tuesday with almost 5bn of new paper primed to print, though bankers and investors are warning that the market could soon sag under the sheer weight of supply.

10 May 2016

Johnson & Johnson ordered to pay $55 mln in talc-powder trial

NEW YORK Johnson & Johnson was ordered by a U.S. jury on Monday to pay $55 million to a woman who said that using the company’s talc-powder products for feminine hygiene caused her to develop ovarian cancer.

03 May 2016

Earnings vs. Estimates